INM SEC Filings
SEC filings for INM. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 8-K | Sep 19, 2026 | 0001213900-26-101492EDGAR |
| 8-K | Jul 23, 2026 | 0001213900-26-080414EDGAR |
| 8-KAIOn July 6, 2026, InMed Pharmaceuticals and Mentari Therapeutics signed Amendment No. 1 to their May 19, 2026 all-stock merger agreement. | Jul 11, 2026 | 0001213900-26-077127EDGAR |
| 8-K | Jun 10, 2026 | 0001062993-26-003132EDGAR |
| 8-K | May 19, 2026 | 0001062993-26-002787EDGAR |
| 8-K | May 19, 2026 | 0001213900-26-058795EDGAR |
| 8-K | May 7, 2026 | 0001062993-26-002371EDGAR |
| 8-K | Apr 28, 2026 | 0001213900-26-048064EDGAR |
| 8-K | Apr 4, 2026 | 0001213900-26-039943EDGAR |
| 8-K | Mar 31, 2026 | 0001062993-26-001697EDGAR |
| 8-K | Mar 23, 2026 | 0001062993-26-001567EDGAR |
| 8-KAIInMed Pharmaceuticals furnished a 2026 pharmaceutical development outlook under Regulation FD. | Mar 9, 2026 | 0001062993-26-001347EDGAR |
| 8-KAIOn March 4, 2026, InMed Pharmaceuticals' board approved the wind down and exit of BayMedica LLC's commercial operations, the company's only revenue-generating business, because H.R. | Mar 7, 2026 | 0001213900-26-024752EDGAR |
| 8-K | Feb 12, 2026 | 0001062993-26-000819EDGAR |
| 8-K | Dec 18, 2025 | 0001062993-25-017390EDGAR |
| 8-KAIInMed Pharmaceuticals disclosed on December 12, 2025 that H.R. | Dec 15, 2025 | 0001213900-25-121497EDGAR |
| 8-KAIOn November 18, 2025, InMed Pharmaceuticals announced successful completion of its first large animal pharmacokinetic studies of the oral formulation of INM-901, its Alzheimer's disease candidate. | Nov 20, 2025 | 0001213900-25-112644EDGAR |
| 8-K | Oct 17, 2025 | 0001213900-25-099529EDGAR |
Never miss a INM filing.
Get an email when INM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.